Proteolysis-targeting chimeras present promising ends in prostate most cancers

On this video, Alexander Chehrazi-Raffle, MD, discusses the outcomes of a part 1/part 2 examine into proteolysis-targeting chimeras in prostate most cancers therapy, introduced at ASCO Annual Assembly.

Chehrazi-Raffle, a medical oncologist on the Metropolis of Hope Duarte Most cancers Middle, noticed “encouraging” numbers in the usage of the PROTAC ARV-766 in metastatic castration-resistant prostate most cancers.

“On this affected person inhabitants, that’s fairly spectacular as a result of these are closely pretreated sufferers on a number of traces of remedy previous to this therapy, so I believe it does characterize a possible novel focused technique that could be within the pipeline within the months to years to come back,” Chehrazi-Raffle mentioned.

Printed by:

Add subject to e mail alerts

Obtain an e mail when new articles are posted on

Please present your e mail tackle to obtain an e mail when new articles are posted on .

“
data-action=”subscribe”>
Subscribe

We had been unable to course of your request. Please strive once more later. In the event you proceed to have this problem please contact customerservice@slackinc.com.

Again to Healio